OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,390.00
-210.00 (-2.19%)
At close: Apr 28, 2026
48.34%
Market Cap 165.70B
Revenue (ttm) 87.16B
Net Income (ttm) 11.36B
Shares Out 17.65M
EPS (ttm) 730.00
PE Ratio 12.86
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 111,894
Average Volume 579,884
Open 9,860.00
Previous Close 9,600.00
Day's Range 9,380.00 - 9,860.00
52-Week Range 5,950.00 - 20,750.00
Beta 0.45
RSI 41.69
Earnings Date Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 159
Stock Exchange KOSDAQ
Ticker Symbol 131030
Full Company Profile

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.

Financial Statements

News

There is no news available yet.